USANA 2024 Revenue 7% Down To $855 Million

USANA Health Sciences, Inc. (NYSE: USNA) (the “Company”) today announced financial results for its fiscal fourth quarter and fiscal year ended December 28, 2024.

The Company completed the acquisition of a 78.8% controlling ownership stake of Hiya Health Products, LLC (“Hiya”) on December 23, 2024. Consequently, the Company’s fourth quarter and fiscal year 2024 include the effect of less than a week of Hiya’s operating results, which were not significant to the Company’s consolidated results for the same periods.

In light of the Hiya acquisition, the Company is now including metrics for Adjusted diluted EPS(1) and Adjusted EBITDA(2). Net earnings, Diluted EPS, Adjusted diluted EPS(1) and Adjusted EBITDA(2) in this press release represent amounts attributable to USANA.

Key Financial Results and Guidance

Fourth Quarter 2024 vs. Fourth Quarter 2023

• Net sales of $214 million versus $221 million.
• Net earnings of $4.5 million as compared to $16.8 million.
• Diluted EPS of $0.23 as compared with $0.87.
• Adjusted diluted EPS⁽¹⁾ of $0.64 as compared with $0.87.
• Adjusted EBITDA⁽²⁾ of $25 million versus $32 million.
• USANA Active Customers of 454,000 versus 483,000.

Fiscal Year 2024 vs. Fiscal Year 2023

• Net sales of $855 million as compared with $921 million.
• Net earnings of $42.0 million as compared to $63.8 million.
• Diluted EPS of $2.19 versus $3.30.
• Adjusted diluted EPS⁽¹⁾ of $2.59 as compared with $3.30.
• Adjusted EBITDA⁽²⁾ of $110 million versus $128 million.

Fiscal Year 2025 Outlook

• Consolidated net sales between $920 million and $1.0 billion, or 8% – 17% growth.
• Net earnings between $29 million and $41 million.
• Diluted EPS between $1.50 and $2.20.
• Adjusted Diluted EPS⁽¹⁾ between $2.35 and $3.00.
• Adjusted EBITDA⁽²⁾ between $107 million and $123 million.

“USANA delivered fourth quarter results above our internal expectations, highlighted by 7% sequential net sales growth,”

said Jim Brown, President and Chief Executive Officer.

“Positive momentum in the Americas & Europe region generated year-over-year and sequential sales growth in this region while performance in our Asia Pacific region declined slightly and was in line with our expectations. On a consolidated basis, we generated solid cash flow during the quarter and our balance sheet remains in a healthy net cash position. Overall, we delivered solid performance to finish the year and are confident in our ability to build on this performance in 2025.”

About USANA

USANA (NYSE:USNA) prides itself on providing consumers with quality nutritional and lifestyle products. From its award-winning supplements to its innovative Celavive skincare and Active Nutrition lines, USANA has proven for over 30 years why it’s a company you can trust. How about giving us a try? Shop at USANA.com or learn more at whatsupUSANA.com.